Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) from a strong sell rating to a sell rating in a research note released on Monday,Wall Street Zen reports.
A number of other equities research analysts have also weighed in on EPRX. Royal Bank Of Canada assumed coverage on Eupraxia Pharmaceuticals in a research report on Monday, November 9th. They set an “outperform” rating and a $14.00 target price for the company. Stifel Nicolaus set a $25.00 price target on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. Wedbush began coverage on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. They set an “outperform” rating and a $17.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 8th. Finally, HC Wainwright lifted their price objective on Eupraxia Pharmaceuticals from $11.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $18.00.
View Our Latest Analysis on EPRX
Eupraxia Pharmaceuticals Stock Down 9.9%
NASDAQ EPRX opened at $7.34 on Monday. Eupraxia Pharmaceuticals has a 12 month low of $5.63 and a 12 month high of $9.32. The company’s 50-day moving average price is $7.62 and its 200-day moving average price is $7.23. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.00 and a current ratio of 12.25.
Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03. As a group, sell-side analysts expect that Eupraxia Pharmaceuticals will post -0.86 earnings per share for the current year.
Institutional Trading of Eupraxia Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its holdings in Eupraxia Pharmaceuticals by 28.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $133,000 after buying an additional 3,500 shares during the period. Persistent Asset Partners Ltd purchased a new stake in Eupraxia Pharmaceuticals during the second quarter worth $25,000. AXQ Capital LP boosted its holdings in Eupraxia Pharmaceuticals by 34.2% during the second quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock worth $140,000 after buying an additional 5,390 shares in the last quarter. BlackRock Inc. acquired a new stake in Eupraxia Pharmaceuticals during the second quarter valued at $40,000. Finally, Ingalls & Snyder LLC grew its position in Eupraxia Pharmaceuticals by 10.2% during the third quarter. Ingalls & Snyder LLC now owns 75,450 shares of the company’s stock valued at $687,000 after buying an additional 7,000 shares during the period.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.
Recommended Stories
- Five stocks we like better than Eupraxia Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
